Combinatorial therapies seek to expand response rates2, with an emerging interest in innate immune agonists, such as toll-like receptor (TLR)3,4 and STimulator of INterferon Genes (STING) agonists5–7, to drive intratumoral antigen-presenting cell (APC) activation and tumor-antigen presentation to effector T cells. The gene discussed is STING1; the disease is neoplasm.